Notably, the HER2-targeting drugs, lapatinib, neratinib, trastuzumab, and pertuzumab (Figure 23) have all been shown to induce anti-proliferative effects in feline mammary carcinoma cell lines in vitro, with synergistic effects observed when combination therapies were used [209,210]. This evidence concerns the gene ERBB2 and breast carcinoma.